Compare Davita Inc (DVA) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs SkyWest Inc — how do they compare? Davita Inc trades at $178.35 (market cap $11.38B), while SkyWest Inc trades at $107.89 (market cap $4.19B). The key difference: Davita Inc is far larger — about 2.7× SkyWest Inc's market cap, and SkyWest Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | SKYW | |
|---|---|---|
Market Cap | $11.38B | $4.19B |
Sector | Health | Technology |
52-Week High | $240.96 | $123.72 |
52-Week Low | $103.87 | $78.40 |
Enterprise Value | $24.10B | $5.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $181.72, down 1.07% on the day, with technical indicators showing a mixed but overall bullish signal. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.02 surpassing estimates. Revenue growth is steady, reaching $13.64B in 2025, though net income margin has fluctuated. Analyst sentiment is cautiously optimistic with a consensus price target of $232.25, representing significant upside potential from current levels.
The outlook for DVA is positive, driven by strong volume growth and strategic execution, but faces risks from reimbursement pressures and a high debt load. Investment opportunity lies in the valuation discount to analyst targets and consistent earnings beats, while key risks include payer mix challenges and macroeconomic factors affecting healthcare spending.
SkyWest (SKYW) trades at $107.23, down 0.41% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows solid fundamentals with a P/E of 10.72 and net income margin of 9.78%, though Q2 2026 earnings missed estimates. Recent news highlights executive stock sales amid company buybacks, while analyst consensus remains positive with a $109.33 price target. Cash flow improved in 2026 to a net positive $33 million from a $105 million deficit in 2025.
The outlook for SKYW is cautiously optimistic, supported by undervalued metrics and bullish analyst ratings, but risks include earnings volatility and insider selling. Investment opportunity lies in its low valuation and operational cash flow growth, though investors should monitor fuel cost pressures and competitive dynamics in the airline industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
